15117 Quality of life impact in adolescent patients with moderate to severe atopic dermatitis: Screening data from the LIBERTY AD ADOL trial

Background: Dupilumab is approved in certain patients with AD, asthma, and chronic rhinosinusitis with nasal polyposis. We report on quality of life (QoL) at screening in adolescents with AD (12-17 years) from a randomized, double-blind, placebo-controlled, phase 3 study (LIBERTY AD ADOL; NCT03054428).